Co-diagnostics vs Pulse Biosciences
Co-diagnostics is the larger business, with $622,489 of revenue in fiscal 2025 against $350,000 for Pulse Biosciences (1.8 times as much). Co-diagnostics kept more of each dollar of sales as profit: a net margin of -7533.6% against -20794.6%.
| Latest fiscal year | Co-diagnosticsCODX, 2025 | Pulse BiosciencesPLSE, 2025 |
|---|---|---|
| Revenue | $622,489 | $350,000 |
| Revenue growth | -84.1% | — |
| Net income | −$46.9m | −$72.8m |
| Operating margin | -8058.8% | — |
| Net margin | -7533.6% | -20794.6% |
| Return on equity | -125.9% | -74.4% |
| Free cash flow | −$29.8m | −$54.4m |
| Cash | $11.9m | $80.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | 116 |
| Market value | $1.9m | $3.66bn |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 8 buys, 7 sales |